Rocket Pharmaceuticals, Inc. Warrant (RCKTW)

• Market cap: $4.91M
• 1 day: 14.43%
• 5 days: -5.93%
• 1 month: 17.65%
• 3 months: -38.58%
• 6 months: 83.27%
• Year to date: -5.93%
• 1 year: -62.87%
• 5 years: -84.67%
• 10 years: -84.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

30% more funds holding

Funds holding: 10 [Q4 2024] → 13 (+3) [Q1 2025]

0.23% less ownership

Funds ownership: 2.35% [Q4 2024] → 2.12% (-0.23%) [Q1 2025]

35% less capital invested

Capital invested by funds: $538K [Q4 2024] → $349K (-$189K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2